SPEAKERS >>>

Junxia MIN

Professor, Institute of Translational Medicine, School of Medicine, Zhejiang University, China

Dr. Junxia Min currently serves as a professor at Institute of Translational Medicine, School of Medicine, Zhejiang University, Hangzhou, China. Dr. Min earned her Ph.D. from University of Missouri-Columbia. The key finding during her PhD training was discovered and defined the important roles of sphingolipid metabolic pathway in resistance to platinum-based anticancer drugs. In 2006, Dr. Min went to Harvard Medical School for her postdoctoral training at the Department of Medicine, Brigham and Women’s Hospital. She identified and characterization EZH2-DAB2IP in promoting prostate cancer tumorigenesis and progression. Since 2010, Dr. Min joined Novartis Department of Oncology as a group leader at Cambridge, U.S.A. Dr. Min's group focused on target identification and validation.

Prof. Min’s research interest is mainly focused on four areas: 1. to identify novel cancer therapeutics, including molecular targeted therapy and immunotherapy; 2. to elucidate molecular mechanisms of resistance to targeted cancer therapeutics; 3. to explore genetic factors of longevity and related phenotypes between genders; and 4. to design effective interventions for improving health expectancy for personalized health care.